Abrysvo Data In Younger Adults Could Give Pfizer An Edge Over GSK

 
• By Jessica Merrill
  
RSV
Pfizer announced positive Phase III data for its RSV vaccine Abrysvo. • Source: Shutterstock

More from Anti-infective

More from Therapy Areas